Cargando…

SLC37A4‐CDG: Second patient

Recently, a disorder caused by the heterozygous de novo c.1267C>T (p.R423*) substitution in SLC37A4 has been described. This causes mislocalization of the glucose‐6‐phosphate transporter to the Golgi leading to a congenital disorder of glycosylation type II (SLC37A4‐CDG). Only one patient has bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Matthew P., Quelhas, Dulce, Leão‐Teles, Elisa, Sturiale, Luisa, Rymen, Daisy, Keldermans, Liesbeth, Race, Valérie, Souche, Erika, Rodrigues, Esmeralda, Campos, Teresa, Van Schaftingen, Emile, Foulquier, François, Garozzo, Domenico, Matthijs, Gert, Jaeken, Jaak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932867/ https://www.ncbi.nlm.nih.gov/pubmed/33728255 http://dx.doi.org/10.1002/jmd2.12195

Ejemplares similares

SLC35A2-CDG: Novel variant and review
por: Quelhas, Dulce, et al.
Publicado: (2021)

COG5-CDG: expanding the clinical spectrum
por: Rymen, Daisy, et al.
Publicado: (2012)

Correction: COG5-CDG: expanding the clinical spectrum
por: Rymen, Daisy, et al.
Publicado: (2013)

CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking
por: Wilson, Matthew P, et al.
Publicado: (2022)

MAN1B1 Deficiency: An Unexpected CDG-II
por: Rymen, Daisy, et al.
Publicado: (2013)

COG6‐CDG: Novel variants and novel malformation
por: Cirnigliaro, Lara, et al.
Publicado: (2022)

Golgi function and dysfunction in the first COG4-deficient CDG type II patient
por: Reynders, Ellen, et al.
Publicado: (2009)

Genotype-Phenotype Correlations in PMM2-CDG
por: Vaes, Laurien, et al.
Publicado: (2021)

ALG11-CDG: Three novel mutations and further characterization of the phenotype
por: Regal, L., et al.
Publicado: (2014)

A novel mutation and first report of dilated cardiomyopathy in ALG6-CDG (CDG-Ic): a case report
por: Al-Owain, Mohammed, et al.
Publicado: (2010)

Ophthalmological and electrophysiological findings in monozygotic twin sisters with phosphomannomutase 2 deficiency (PMM2-CDG) over a period of 37 years
por: Van Hees, Ines, et al.
Publicado: (2019)

PMM2‐CDG and nephrotic syndrome: A case report
por: Banderali, Giuseppe, et al.
Publicado: (2022)

How to find and diagnose a CDG due to defective N-glycosylation
por: Lefeber, Dirk J., et al.
Publicado: (2011)

Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG)
por: Pettinato, Fabio, et al.
Publicado: (2021)

Clinical, molecular and glycophenotype insights in SLC39A8-CDG
por: Bonaventura, Eleonora, et al.
Publicado: (2021)

CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)

Congenital disorders of glycosylation (CDG): state of the art in 2022
por: Francisco, Rita, et al.
Publicado: (2023)

Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1‐CDG)
por: Altassan, Ruqaiah, et al.
Publicado: (2022)

ALG8-CDG: novel patients and review of the literature
por: Höck, Michaela, et al.
Publicado: (2015)

ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG
por: Wong, Sunnie Yan-Wai, et al.
Publicado: (2017)

Hypoglycemia in CDG patients due to PMM2 mutations: Follow up on hyperinsulinemic patients
por: Moravej, Hossein, et al.
Publicado: (2019)

Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016)

Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG)
por: Brasil, Sandra, et al.
Publicado: (2022)

SLC37A4-CDG: Mislocalization of the glucose-6-phosphate transporter to the Golgi causes a new congenital disorder of glycosylation
por: Marquardt, Thorsten, et al.
Publicado: (2020)

Correction: Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016)

D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial
por: Witters, Peter, et al.
Publicado: (2021)

New Insights into Immunological Involvement in Congenital Disorders of Glycosylation (CDG) from a People-Centric Approach
por: Francisco, Rita, et al.
Publicado: (2020)

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
por: Serrano, Mercedes, et al.
Publicado: (2015)

GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients
por: de la Morena-Barrio, Maria E, et al.
Publicado: (2013)

Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
por: Lebredonchel, Elodie, et al.
Publicado: (2021)

A PMM2-CDG caused by an A108V mutation associated with a heterozygous 70 kilobases deletion case report
por: Lebredonchel, E., et al.
Publicado: (2022)

Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG
por: Witters, Peter, et al.
Publicado: (2020)

Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis
por: Sturiale, Luisa, et al.
Publicado: (2021)

Nijmegen paediatric CDG rating scale: a novel tool to assess disease progression
por: Achouitar, Samira, et al.
Publicado: (2011)

CDG – an update
por: Morava, Eva, et al.
Publicado: (2011)

Four New Cases of SLC35A2-CDG With Novel Mutations and Clinical Features
por: Abuduxikuer, Kuerbanjiang, et al.
Publicado: (2021)

N-Glycoprofiling of SLC35A2-CDG: Patient with a Novel Hemizygous Variant
por: Kodríková, Rebeka, et al.
Publicado: (2023)

SRD5A3 defective congenital disorder of glycosylation: clinical utility gene card
por: Jaeken, Jaak, et al.
Publicado: (2020)

Mutations in the X-linked ATP6AP2 cause a glycosylation disorder with autophagic defects
por: Rujano, Maria A., et al.
Publicado: (2017)

SRD5A3-CDG: Emerging Phenotypic Features of an Ultrarare CDG Subtype
por: Kamarus Jaman, Nazreen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h56ou78b6hqf8j6ht6vu23p9n5